Kybernin P (Antithrombin Iii)

Antithrombin III is a natural inhibitor of several clotting enzymes, most notably thrombin (factor IIa) and factor Xa. By binding to these enzymes, it blocks their activity, which reduces fibrin formation and limits clot propagation. Its inhibitory effect is amplified when heparin is present, providing rapid anticoagulation.

The dose of Kybernin P is individualized by the prescribing clinician based on the patient’s plasma antithrombin level, body weight, and clinical situation. Dosing calculations are performed to achieve target antithrombin activity, and the exact amount and infusion rate are determined at the point of care.

Safety data for Kybernin P in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case carefully and discuss potential risks with the patient.

To order Kybernin P, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, cold‑chain shipping details, and necessary import documentation.

Kybernin P is a purified antithrombin concentrate offering consistent activity and volume, unlike fresh‑frozen plasma which contains variable antithrombin levels and additional plasma proteins. Compared with other concentrates, Kybernin P provides a standardized, virus‑inactivated product that can be dosed precisely under controlled conditions.

Kybernin P must be stored refrigerated at 2‑8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to administration, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the infusion protocol.

Kybernin P is given by intravenous infusion under the supervision of a qualified healthcare professional. The prescribing clinician determines the infusion volume and rate based on the patient’s antithrombin activity and clinical needs. Administration is typically performed in a hospital or clinic setting with appropriate monitoring for adverse reactions.

The most serious risks include severe bleeding, anaphylactic or hypersensitivity reactions, and disseminated intravascular coagulation. These events can be life‑threatening and require immediate medical attention. Patients should be closely monitored during and after infusion for signs of hemorrhage or allergic response.

Kybernin P is contraindicated in individuals with known hypersensitivity to antithrombin III, any component of the formulation, or in patients with uncontrolled active bleeding where additional anticoagulation could worsen the condition. Caution is also advised for patients with severe hepatic dysfunction or those receiving incompatible medications.